Period:
Draw Mode:
| Volume | 3,046 |
|
|||||
| News | - | ||||||
| Day High | 0.76 | Low High |
|||||
| Day Low | 0.71 | ||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| AgeX Therapeutics Inc | AGE | AMEX | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.0281 | 3.84% | 0.76 | 14:07:48 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 0.71 | 0.71 | 0.76 | 0.7319 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 52 | 3,046 | $ 0.7448327 | $ 2,269 | - | 0.372 - 1.00 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 14:07:19 | 1 | $ 0.7611 | USD |
AgeX Therapeutics Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 28.84M | 37.95M | - | 34k | -10.46M | -0.28 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
AgeX Therapeutics News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical AGE Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 0.6903 | 0.84 | 0.6871 | 0.7858271 | 33,849 | 0.0697 | 10.1% |
| 1 Month | 0.7301 | 0.84 | 0.6333 | 0.7536405 | 26,008 | 0.0299 | 4.1% |
| 3 Months | 0.91 | 0.9381 | 0.6333 | 0.7617726 | 24,752 | -0.15 | -16.48% |
| 6 Months | 0.66 | 1.00 | 0.372 | 0.6791483 | 23,543 | 0.10 | 15.15% |
| 1 Year | 0.596 | 1.00 | 0.372 | 0.652598 | 23,490 | 0.164 | 27.52% |
| 3 Years | 0.9375 | 3.93 | 0.372 | 2.21 | 599,608 | -0.1775 | -18.93% |
| 5 Years | 1.13 | 5.95 | 0.372 | 2.16 | 441,645 | -0.37 | -32.74% |
AgeX Therapeutics Description
| AgeX Therapeutics Inc is a biotechnology company engaged in the development and commercialization of novel therapeutics targeting human aging. The firm through its PureStem and induced Tissue Regeneration (iTR) technologies develop medicines designed to address some of the unsolved problems in aging. Its PureStem derived cell-based therapeutic candidates in development are AGEX-VASC1, AGEX-BAT1 and AGEX-iTR1547. |